1H-吡咯[3,2-B]吡啶-5-甲腈 | 146767-63-7

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 1H-吡咯[3,2-B]吡啶-5-甲腈
• 英文名称: 1H-pyrrolo[3,2-b]pyridine-5-carbonitrile
• CAS: 146767-63-7
• 化学式: C₈H₅N₃
• mdl: MFCD09909831
• 分子量: 143.148
• InChiKey: YSSSUMUGHHKGCO-UHFFFAOYSA-N

物化性质

• 沸点：
  373.2±22.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P280,P305+P351+P338

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1H-Pyrrolo[3,2-B]Pyridine-5-Carbonitrile
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 143,15 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
1H-Pyrrolo[3,2-B]Pyridine-5-Carbonitrile
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
1H-Pyrrolo[3,2-B]Pyridine-5-Carbonitrile
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  1H-吡咯[3,2-B]吡啶-5-甲腈 在 4-二甲氨基吡啶 、 碘 、 potassium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 tert-butyl 5-cyano-3-iodo-1H-pyrrolo[3,2-b]pyridine-1-carboxylate
  参考文献：
  名称：

  [EN] 4-AZAINDOLE DERIVATIVES
  [FR] DÉRIVÉS DE 4-AZAINDOLE

  摘要：

  4-氮杂吲哚衍生物是肌氨酸乙酰胆碱受体（mAChR）M1的调节剂，可能对预防或疾病修饰或症状性治疗与神经系统疾病（如阿尔茨海默病（AD）或带有Lewy小体的痴呆症（DLB））相关的认知缺陷有效，并且包括4-氮杂吲哚衍生物作为活性成分的药物组合物。

  公开号：

  WO2015049574A1
• 作为产物：
  描述：

  3-(4-fluoro-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-4-methylbenzoic acid 、 1-(1H-pyrrolo[3,2-b]pyridin-5-yl)cyclopropanamine 以obtained from 1H-pyrrolo[3,2-b]pyridine-5-carbonitrile by the reaction的产率得到1H-吡咯[3,2-B]吡啶-5-甲腈
  参考文献：
  名称：

  Compounds for the treatment of hepatitis C

  摘要：

  本公开提供I式化合物，包括其盐，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，可能对治疗HCV感染者有用。

  公开号：

  US08354410B2

文献信息

• New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity
  作者：Dong-Jin Hwang、Yali He、Suriyan Ponnusamy、Michael L. Mohler、Thirumagal Thiyagarajan、Iain J. McEwan、Ramesh Narayanan、Duane D. Miller

  DOI：10.1021/acs.jmedchem.8b00973

  日期：2019.1.24

  propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and

  在寻找晚期前列腺癌（PCs）的小分子治疗方法的过程中，发现了一系列新颖的吲哚基和吲哚基丙酰胺（II和III系列）作为选择性雄激素受体降解剂（SARDs）。对雄激素受体（AR）拮抗剂（1）和激动剂（2）丙酰胺的初步研究产生了具有新型SARD活性但代谢稳定性较差的叔苯胺（3）。环化至II和III产生亚微摩尔的AR拮抗作用，并对AR和AR剪接变体（AR SV）产生选择性的蛋白质降解。二和三维持对enzalutamide耐药（Enz-R）突变的ARs和PC细胞的效力，并且对Enz-R异种移植物有效，表明它们具有治疗晚期PCs的潜力。新型SARD的设计，合成和生物学活性，可潜在地用于治疗各种PC，包括去势抵抗性，Enz-R和/或AR SV依赖性的晚期PC，这些已知PC通常无法用已知的激素疗法治疗讨论。
• 4-Azaindole Derivatives
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20150094328A1

  公开（公告）日：2015-04-02

  4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

  4-氮杂吲哚衍生物是肌胆碱受体（mAChR）M1的调节剂，可能对预防或疾病修饰或症状性治疗与神经系统疾病如阿尔茨海默病（AD）或带有Lewy小体的痴呆症相关的认知缺陷有效，并且包括4-氮杂吲哚衍生物作为活性成分的药物组合物。
• AZAINDOLE DERIVATIVES
  申请人：Heinrich Timo

  公开号：US20110207732A1

  公开（公告）日：2011-08-25

  Compounds of the formula (I), in which X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 and R 4 have the meanings indicated in Claim 1 , are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.

  式(I)的化合物，其中X1、X2、X3、X4、R1、R2、R3和R4具有权利要求1所示的含义，是酪氨酸激酶的抑制剂，特别是Met激酶的抑制剂，可以用于治疗肿瘤等疾病。
• A synthesis of 5-carboxamidopyrrolo[3,2-<i>b</i>]pyridine
  作者：John E. Macor、Ronald Post、Kevin Ryan

  DOI：10.1002/jhet.5570290616

  日期：1992.10

  A four-step synthesis of 5-carboxamidopyrrolo[3,2-b]pyridine (3) from pyrrolo[3,2-b]pyridine (4) is described (45% overall yield). The one-step conversion of the N-oxide 6 of the pyrrolo[3,2-b]pyridine 5 leads to the 5-cyanopyrrolo[3,2-b]pyridine 7. The cyano group is hydrolyzed to afford the title compound 3, which is the 4-aza analog of the indole backbone in 5-carboxamidotryptamine, a potent agonist

  5- carboxamidopyrrolo [3,2的四步合成b ]吡啶（3从吡咯并[3,2-）b ]吡啶（4）中描述了（45％总收率）。吡咯并[3，2- b ]吡啶5的N-氧化物6的一步转化导致5-氰基吡咯并[3，2 - b ]吡啶7。氰基水解得到标题化合物3。，它是5-羧酰胺基色胺（一种神经递质5-羟色胺的有效激动剂）中吲哚骨架的4-氮杂类似物。
• Compounds for the Treatment of Hepatitis C
  申请人：Yeung Kap-Sun

  公开号：US20120059019A1

  公开（公告）日：2012-03-08

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

  本公开提供式I化合物及其盐，以及使用该化合物的组合物和方法。该化合物对丙型肝炎病毒（HCV）具有活性，可用于治疗HCV感染者。